STK1p as a prognostic biomarker for overall survival in non-small-cell lung carcinoma, based on real-world data

AIM: A prospective investigation of serum thymidine kinase 1 concentration (STK1p) was performed to evaluate its prognostic value in patients with non-small-cell lung carcinoma (NSCLCs). PATIENTS & METHODS: The STK1p values of 127 patients were determined by an enhanced chemiluminescent dot blot...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Zhenxin, Zhang, Guoqing, Li, Zhongcheng, Li, Jin, Ma, Hongbo, Hei, Ailian, Jiao, Shunchang, Hu, Yi, Sun, Shengjie, Wu, Liangliang, Zhou, Ji, Wang, Yu, He, Ellen, Skog, Sven
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Future Science Ltd 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7849927/
https://www.ncbi.nlm.nih.gov/pubmed/33552542
http://dx.doi.org/10.2144/fsoa-2020-0130
Descripción
Sumario:AIM: A prospective investigation of serum thymidine kinase 1 concentration (STK1p) was performed to evaluate its prognostic value in patients with non-small-cell lung carcinoma (NSCLCs). PATIENTS & METHODS: The STK1p values of 127 patients were determined by an enhanced chemiluminescent dot blot assay. The patients were recruited from March 2011 to December 2017. RESULTS: Kaplan–Meier plot showed that patients with elevated STK1p values had worse overall survival (OS), especially patients of early/middle stages. Multi-variable COX regression showed that STK1p value and combined treatment surgery + chemotherapy were independent prognostic factors for favorable OS. CONCLUSION: STK1p is helpful in predicting OS of early/middle stages (I–IIIA) NSCLCs patients following a nonrandomized individual adapted treatment, but is may be not recommended in advanced stages (IIIB + IV) of NSCLCs.

Ejemplares similares